Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 9/20 | 0.53 |
| ▸ | PLA2G1B | P04054 | 5/20 | 0.47 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.47 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2157014 | 0.92 | PLA2G2A (0.52) | PLA2G2APLA2G1BPLA2G10PLA2G5MTNR1A | |
| SCHEMBL2156650 | 0.86 | PLA2G2A (0.52) | PLA2G2APLA2G1BPLA2G10PLA2G5 | |
| SCHEMBL2157056 | 0.85 | MTNR1B (0.51) | PLA2G2APLA2G1BPLA2G10PLA2G5MTNR1A | |
| SCHEMBL5696981 | 0.82 | PLA2G2A (0.49) | PLA2G2APLA2G1BPLA2G10PLA2G5MTNR1A | |
| SCHEMBL2156844 | 0.82 | PLA2G2A (0.52) | PLA2G2APLA2G1BPLA2G10PLA2G5 | |
| SCHEMBL8502335 | 0.81 | PPARG (0.48) | PLA2G2APLA2G1BPLA2G10PLA2G5MTNR1A | |
| SCHEMBL4789355 | 0.79 | PLA2G1B (0.46) | PLA2G2APLA2G1BMTNR1AMTNR1BPSEN1 | |
| SCHEMBL2156747 | 0.78 | PPARG (0.45) | PLA2G2APLA2G1BPLA2G10PLA2G5MTNR1A | |
| SCHEMBL819950 | 0.78 | PLA2G2A (0.85) | PLA2G2APLA2G1BPLA2G10PLA2G5 | |
| SCHEMBL25136 | 0.78 | MTNR1B (0.60) | PLA2G2APLA2G1BPLA2G10PLA2G5MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2341045-A1 | [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-11H-indol-4-yl]oxy]acetic acid (acyloxy)alkyl or ((alkoxycarbonyl)oxy)alkyl ester as SPLA2 inhibitor | Eli Lilly and Company (US) | 2011-07-06 | — | — | EP | disclosed |
| EP-1950200-A1 | [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-11H-indol-4-yl]oxy]acetic acid methyl ester as sPLA2 inhibitor | ELI LILLY AND COMPANY (US) | 2008-07-30 | — | — | EP | disclosed |
| US-6433001-B1 | SEPTIC SHOCK, ALLERGIC RHINITIS, RHEUMATIC ARTHRITIS, ADULT RESPIRATORY DISTRESS SYNDROME, BRONCHIAL ASTHMA, TRAUMA, AND PANCREATITIS TREATMENT | ELI LILLY AND COMPANY | 2002-08-13 | — | — | US | disclosed |
| EP-0675110-B1 | 1H-Indole-3-glyoxylamide sPLA2 inhibitors | LILLY CO ELI (US) | 2002-07-10 | — | — | EP | disclosed |
| EP-1197484-A2 | 1H-Indole-3-glyoxylamide sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 2002-04-17 | — | — | EP | disclosed |
| EP-1081135-A2 | 1H-indole-3-glyoxylamide spla2 inhibitors | ELI LILLY AND COMPANY (US) | 2001-03-07 | — | — | EP | disclosed |
| US-6175021-B1 | HUMAN NON-PANCREATIC SECRETORY PHOSPHOLIPASE A2 (SPLA2); INHIBITS RELEASE OF ARACHIDONIC ACID TO TREAT SEPTIC SHOCK; ((3-(2-AMINO-1,2-DIOXOETHYL)-2-METHYL-1-(PHENYLMETHYL)-1H-INDOL-4 -YL)OXYLACETIC ACID, FOR EXAMPLE | ELI LILLY AND COMPANY | 2001-01-16 | — | — | US | disclosed |
| US-5919810-A | SEPTIC SHOCK | ELI LILLY AND COMPANY (US) | 1999-07-06 | — | — | US | disclosed |
| US-5919943-A | INHIBITION OF SPLA2 | ELI LILLY AND COMPANY (US) | 1999-07-06 | — | — | US | disclosed |
| US-5733923-A | SECRETORY PANCREATIC PHOSPHOLIPASE A2 | ELI LILLY AND COMPANY (US) | 1998-03-31 | — | — | US | disclosed |
| US-5654326-A | SEPTIC SHOCK; HUMAN NONPANCREATIC SECRETORY PHOSPHOLIPASE | ELI LILLY AND COMPANY (US) | 1997-08-05 | — | — | US | disclosed |
| EP-0675110-A1 | 1H-Indole-3-glyoxylamide sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 1995-10-04 | — | — | EP | disclosed |